Monitoring Report: Respiratory Viruses - February 2024 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Charlotte Baker, DrPH, MPH, CPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky Truveta, Inc 1745 114th Ave SE, Bellevue, WA 98004

Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through February 25, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and February 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 483,928 hospitalizations of 449,124 unique patients who tested positive for a respiratory virus between October 01, 2019 and February 25, 2024.


Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout February 2024 (-20.0%) compared to January 2024. While the main contributors COVID- and influenza-associated hospitalizations decreased (-26.5% and -22.7%), all other respiratory viruses increased, with HMPV increasing quickly (117.2%). For infants and children, the overall and individual rate of hospitalization decreased. Rhinovirus-associated hospitalizations account for the largest percentage of hospitalizations with 1.2% in the last week of February 2024. The population over 65 years of age also saw an overall decrease in respiratory virus-associated hospitalizations (-19.9%) like the overall population. However, HMPV-associated hospitalizations increased rapidly (+204.6%).

Discussion: We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall, including for the two high-risk populations we studied. In February 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population. However, HMPV-associated hospitalization

rose quickly in the older adult population, and we will continue to monitor its trends in the upcoming month.

Trends in Surveillance


Overall population



Date	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
January 22, 2024	5.0%	2.3%	1.7%	0.1%	0.1%	0.6%	0.4%
February 19, 2024	4.0%	1.7%	1.3%	0.2%	0.1%	0.4%	0.5%
Change (percentage)	-20.0%	-26.5%	-22.7%	+117.2%	+23.1%	-31.8%	+3.3%
Difference (percentage points)	-1.0%	-0.6%	-0.4%	+0.1%	+0.0%	-0.2%	+0.0%

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout February 2024 (20.0% decrease since end of January 2024). This is due to the decrease in COVID- (-26.5%) and influenza-associated hospitalizations (-22.7%). Hospitalizations for all other monitored respiratory viruses increased, including those associated with HPMV, which more than doubled (+117.2%) throughout the month. COVID- and influenza-associated hospitalizations make up 2.3% and 1.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of February 2024, respiratory virus-associated hospitalizations accounted for 4.0% of all hospitalizations.

Infants and children (age 0-4)



For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout February (-28.4%). For individual viruses, associated hospitalizations decreased when counts were above reporting thresholds. In the last week of February, 2.8% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.2%).

-27.5%

-0.1%

-48.1%

-0.6%

-27.9%

-0.5%

Older adults (age 65 and over)

-28.4%


-1.1%

-32.0%

-0.2%

Change (percentage)

Difference (percentage points)



Date	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
January 22, 2024	6.5%	3.6%	1.9%	0.1%	0.1%	0.7%	0.3%
February 19, 2024	5.2%	2.7%	1.5%	0.2%	0.1%	0.5%	0.3%
Change (percentage)	-19.9%	-26.1%	-21.3%	+204.6%	+12.2%	-21.5%	+15.1%
Difference (percentage points)	-1.3%	-1.0%	-0.4%	+0.1%	+0.0%	-0.1%	+0.0%

In the population over 65 years of age, there was a 19.9% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations all increased. HMPV-associated hospitalizations increased by 204.6% compared to the last week of January. In the last week of February, 5.2% of all hospitalizations in this age group were associated with a respiratory virus.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death, especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions, such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and February 25, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on March 14, 2024 and included de-identified patient care data primarily located across ten states: Texas, New York, Florida, California, Michigan, Washington, Illinois, North Carolina, Louisiana, and Wisconsin.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 483,928 hospitalizations of 449,124 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	66,186 (100.00%)	126,731 (100.00%)	123,598 (100.00%)	87,250 (100.00%)	45,359 (100.00%)	449,124 (100.00%)
Age Group						
< 6 months	1,595 (2.41%)	1,423 (1.12%)	2,474 (2.00%)	2,811 (3.22%)	1,481 (3.27%)	9,784 (2.18%)
6 - <12 months	724 (1.09%)	486 (0.38%)	1,012 (0.82%)	1,323 (1.52%)	695 (1.53%)	4,240 (0.94%)
1 - <2 years	911 (1.38%)	808 (0.64%)	1,525 (1.23%)	1,900 (2.18%)	920 (2.03%)	6,064 (1.35%)
2 - 4 years	1,132 (1.71%)	913 (0.72%)	2,187 (1.77%)	2,842 (3.26%)	1,114 (2.46%)	8,188 (1.82%)
5 - 17 years	1,156 (1.75%)	1,751 (1.38%)	2,813 (2.28%)	3,218 (3.69%)	1,471 (3.24%)	10,409 (2.32%)
18 - 49 years	14,143 (21.37%)	30,229 (23.85%)	27,017 (21.86%)	12,801 (14.67%)	6,511 (14.35%)	90,701 (20.20%)
50 - 64 years	16,200 (24.48%)	31,701 (25.01%)	24,919 (20.16%)	13,472 (15.44%)	7,450 (16.42%)	93,742 (20.87%)
65 - 74 years	12,775 (19.30%)	25,625 (20.22%)	23,795 (19.25%)	16,506 (18.92%)	8,675 (19.13%)	87,376 (19.45%)
75 - 84 years	10,981 (16.59%)	21,793 (17.20%)	23,323 (18.87%)	19,064 (21.85%)	10,049 (22.15%)	85,210 (18.97%)
85+ years	6,569 (9.93%)	12,002 (9.47%)	14,533 (11.76%)	13,313 (15.26%)	6,993 (15.42%)	53,410 (11.89%)
Sex						
Female	33,340 (50.37%)	63,209 (49.88%)	64,448 (52.14%)	45,955 (52.67%)	24,148 (53.24%)	231,100 (51.46%)
Male	32,640 (49.32%)	63,051 (49.75%)	58,762 (47.54%)	41,064 (47.06%)	21,095 (46.51%)	216,612 (48.23%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	205 (0.31%)	470 (0.37%)	380 (0.31%)	229 (0.26%)	116 (0.26%)	1,412 (0.31%)

Race						
White	36,519 (55.18%)	85,576 (67.53%)	85,897 (69.50%)	58,240 (66.75%)	29,807 (65.71%)	296,039 (65.91%)
Black or African American	12,621 (19.07%)	16,993 (13.41%)	15,613 (12.63%)	10,753 (12.32%)	6,004 (13.24%)	61,984 (13.80%)
Asian	2,829 (4.27%)	3,853 (3.04%)	3,975 (3.22%)	3,811 (4.37%)	1,733 (3.82%)	16,201 (3.61%)
Native Hawaiian or Other Pacific Islander	377 (0.57%)	589 (0.46%)	701 (0.57%)	488 (0.56%)	263 (0.58%)	2,418 (0.54%)
American Indian or Alaska Native	304 (0.46%)	596 (0.47%)	724 (0.59%)	588 (0.67%)	244 (0.54%)	2,456 (0.55%)
Other Race	9,109 (13.76%)	13,354 (10.54%)	11,396 (9.22%)	8,695 (9.97%)	4,389 (9.68%)	46,943 (10.45%)
Declined to answer	360 (0.54%)	618 (0.49%)	583 (0.47%)	461 (0.53%)	318 (0.70%)	2,340 (0.52%)
Unknown	4,067 (6.14%)	5,152 (4.07%)	4,709 (3.81%)	4,214 (4.83%)	2,601 (5.73%)	20,743 (4.62%)
Ethnicity						
Hispanic or Latino	11,559 (17.46%)	18,445 (14.55%)	15,305 (12.38%)	11,576 (13.27%)	6,073 (13.39%)	62,958 (14.02%)
Not Hispanic or Latino	47,367 (71.57%)	97,107 (76.62%)	99,581 (80.57%)	70,068 (80.31%)	36,388 (80.22%)	350,511 (78.04%)
Declined to answer	354 (0.53%)	702 (0.55%)	648 (0.52%)	510 (0.58%)	299 (0.66%)	2,513 (0.56%)
Unknown	6,906 (10.43%)	10,477 (8.27%)	8,064 (6.52%)	5,096 (5.84%)	2,599 (5.73%)	33,142 (7.38%)
Virus						
COVID	40,942 (61.86%)	119,133 (94.00%)	106,991 (86.56%)	50,403 (57.77%)	21,177 (46.69%)	338,646 (75.40%)
HMPV	2,041 (3.08%)	137 (0.11%)	1,717 (1.39%)	3,537 (4.05%)	710 (1.57%)	8,142 (1.81%)
RSV	4,266 (6.45%)	1,583 (1.25%)	3,409 (2.76%)	6,238 (7.15%)	6,274 (13.83%)	21,770 (4.85%)
influenza	11,764 (17.77%)	165 (0.13%)	3,216 (2.60%)	12,022 (13.78%)	11,104 (24.48%)	38,271 (8.52%)
parainfluenza virus	1,005 (1.52%)	929 (0.73%)	1,616 (1.31%)	3,208 (3.68%)	837 (1.85%)	7,595 (1.69%)
rhinovirus	6,168 (9.32%)	4,784 (3.77%)	6,649 (5.38%)	11,842 (13.57%)	5,257 (11.59%)	34,700 (7.73%)
Comorbidity						
Asthma	5,873 (8.87%)	9,131 (7.21%)	11,173 (9.04%)	10,175 (11.66%)	5,863 (12.93%)	42,215 (9.40%)
Chronic Lung Disease	3,815 (5.76%)	6,307 (4.98%)	6,727 (5.44%)	5,895 (6.76%)	3,444 (7.59%)	26,188 (5.83%)
Chronic Obstructive Pulmonary Disease	7,690 (11.62%)	12,552 (9.90%)	15,778 (12.77%)	13,437 (15.40%)	7,706 (16.99%)	57,163 (12.73%)

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019





Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



COVID-19

Our COVID study population consists of 352,142 hospitalizations of 338,646 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	40,942	119,133	106,991	50,403	21,177	338,646
	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)
Age Group						
< 6 months	89 (0.22%)	571 (0.48%)	1,018 (0.95%)	384 (0.76%)	172 (0.81%)	2,234 (0.66%)
6 - <12 months	n/a	81 (0.07%)	239 (0.22%)	157 (0.31%)	75 (0.35%)	561 (0.17%)
1 - <2 years	13 (0.03%)	135 (0.11%)	301 (0.28%)	136 (0.27%)	71 (0.34%)	656 (0.19%)
2 - 4 years	23 (0.06%)	163 (0.14%)	402 (0.38%)	174 (0.35%)	55 (0.26%)	817 (0.24%)
5 - 17 years	179 (0.44%)	1,000 (0.84%)	1,356 (1.27%)	470 (0.93%)	168 (0.79%)	3,173 (0.94%)
18 - 49 years	10,075 (24.61%)	28,963 (24.31%)	24,674 (23.06%)	7,258 (14.40%)	2,459 (11.61%)	73,429 (21.68%)
50 - 64 years	11,170 (27.28%)	30,682 (25.75%)	22,748 (21.26%)	7,859 (15.59%)	3,057 (14.44%)	75,516 (22.30%)
65 - 74 years	8,406 (20.53%)	24,816 (20.83%)	21,619 (20.21%)	10,635 (21.10%)	4,461 (21.07%)	69,937 (20.65%)

75 - 84 years	7,000 (17.10%)	21,125	21,357	13,475	6,099 (28.80%)	69,056
85+ years	3,978 (9.72%)	(17.73%) 11,597 (9.73%)	(19.96%)	(26.73%) 9,855 (19.55%)	4,560 (21.53%)	(20.39%)
-			(12.41%)			(12.78%)
Sex						
Female	19,855 (48.50%)	59,361 (49.83%)	55,836 (52.19%)	26,339 (52.26%)	10,975 (51.83%)	172,366 (50.90%)
Male	20,964 (51.20%)	59,327 (49.80%)	50,799 (47.48%)	23,927 (47.47%)	10,148 (47.92%)	165,165 (48.77%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	122 (0.30%)	444 (0.37%)	349 (0.33%)	135 (0.27%)	54 (0.25%)	1,104 (0.33%)
Race						
White	20,687 (50.53%)	81,357 (68.29%)	76,041 (71.07%)	35,911 (71.25%)	15,177 (71.67%)	229,173 (67.67%)
Black or African American	8,823 (21.55%)	15,652 (13.14%)	13,202 (12.34%)	5,523 (10.96%)	2,250 (10.62%)	45,450 (13.42%)
Asian	1,802 (4.40%)	3,531 (2.96%)	3,158 (2.95%)	2,022 (4.01%)	774 (3.65%)	11,287 (3.33%)
Native Hawaiian or Other Pacific Islander	220 (0.54%)	529 (0.44%)	527 (0.49%)	206 (0.41%)	76 (0.36%)	1,558 (0.46%)
American Indian or Alaska Native	172 (0.42%)	547 (0.46%)	575 (0.54%)	283 (0.56%)	105 (0.50%)	1,682 (0.50%)
Other Race	6,202 (15.15%)	12,099 (10.16%)	9,120 (8.52%)	4,077 (8.09%)	1,540 (7.27%)	33,038 (9.76%)
Declined to answer	259 (0.63%)	588 (0.49%)	496 (0.46%)	247 (0.49%)	124 (0.59%)	1,714 (0.51%)
Unknown	2,777 (6.78%)	4,830 (4.05%)	3,872 (3.62%)	2,134 (4.23%)	1,131 (5.34%)	14,744 (4.35%)
Ethnicity						
Hispanic or Latino	8,286 (20.24%)	17,142 (14.39%)	12,540 (11.72%)	5,380 (10.67%)	2,135 (10.08%)	45,483 (13.43%)
Not Hispanic or Latino	27,747 (67.77%)	91,380 (76.70%)	86,787 (81.12%)	41,787 (82.91%)	17,655 (83.37%)	265,356 (78.36%)
Declined to answer	241 (0.59%)	668 (0.56%)	571 (0.53%)	295 (0.59%)	131 (0.62%)	1,906 (0.56%)
Unknown	4,668 (11.40%)	9,943 (8.35%)	7,093 (6.63%)	2,941 (5.83%)	1,256 (5.93%)	25,901 (7.65%)
Comorbidity						
Asthma	2,436 (5.95%)	8,072 (6.78%)	8,791 (8.22%)	4,741 (9.41%)	2,251 (10.63%)	26,291 (7.76%)
Chronic Lung Disease	1,710 (4.18%)	5,833 (4.90%)	5,600 (5.23%)	3,214 (6.38%)	1,608 (7.59%)	17,965 (5.30%)
Chronic Obstructive Pulmonary Disease	3,139 (7.67%)	11,620 (9.75%)	13,460 (12.58%)	7,635 (15.15%)	3,670 (17.33%)	39,524 (11.67%)

The rate of COVID-associated hospitalization is shown in Figure 3. Figure 4 shows seasonal trends.

Figure 3: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019





Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by s



Influenza

Our influenza study population consists of 42,789 hospitalizations of 38,271 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall			
N	11,764 (100.00%)	165 (100.00%)	3,216 (100.00%)	12,022 (100.00%)	11,104 (100.00%)	38,271 (100.00%)			
Age Group									
< 6 months	151 (1.28%)	n/a	23 (0.72%)	72 (0.60%)	61 (0.55%)	307 (0.80%)			
6 - <12 months	96 (0.82%)	n/a	17 (0.53%)	79 (0.66%)	34 (0.31%)	226 (0.59%)			
1 - <2 years	150 (1.28%)	n/a	20 (0.62%)	105 (0.87%)	68 (0.61%)	344 (0.90%)			
2 - 4 years	223 (1.90%)	n/a	58 (1.80%)	256 (2.13%)	156 (1.40%)	696 (1.82%)			
5 - 17 years	362 (3.08%)	n/a	136 (4.23%)	569 (4.73%)	432 (3.89%)	1,504 (3.93%)			
18 - 49 years	2,529 (21.50%)	33 (20.00%)	791 (24.60%)	2,555 (21.25%)	2,415 (21.75%)	8,323 (21.75%)			
50 - 64 years	2,882 (24.50%)	50 (30.30%)	587 (18.25%)	2,401 (19.97%)	2,545 (22.92%)	8,465 (22.12%)			
65 - 74 years	2,296 (19.52%)	27 (16.36%)	617 (19.19%)	2,448 (20.36%)	2,268 (20.43%)	7,656 (20.00%)			
75 - 84 years	1,929 (16.40%)	30 (18.18%)	599 (18.63%)	2,267 (18.86%)	2,079 (18.72%)	6,904 (18.04%)			
85+ years	1,146 (9.74%)	16 (9.70%)	368 (11.44%)	1,270 (10.56%)	1,046 (9.42%)	3,846 (10.05%)			

Sex						
Female	6,421 (54.58%)	93 (56.36%)	1,840 (57.21%)	6,713 (55.84%)	6,146 (55.35%)	21,213 (55.43%)
Male	5,301 (45.06%)	71 (43.03%)	1,370 (42.60%)	5,276 (43.89%)	4,929 (44.39%)	16,947 (44.28%)
Unknown	42 (0.36%)	n/a	n/a	33 (0.27%)	29 (0.26%)	111 (0.29%)
Race						
White	7,201 (61.21%)	99 (60.00%)	2,081 (64.71%)	7,606 (63.27%)	6,744 (60.73%)	23,731 (62.01%)
Black or African American	2,086 (17.73%)	40 (24.24%)	552 (17.16%)	1,907 (15.86%)	1,949 (17.55%)	6,534 (17.07%)
Asian	476 (4.05%)	n/a	94 (2.92%)	435 (3.62%)	387 (3.49%)	1,398 (3.65%)
Native Hawaiian or Other Pacific Islander	56 (0.48%)	n/a	36 (1.12%)	88 (0.73%)	74 (0.67%)	256 (0.67%)
American Indian or Alaska Native	50 (0.43%)	n/a	33 (1.03%)	102 (0.85%)	55 (0.50%)	240 (0.63%)
Other Race	1,248 (10.61%)	10 (6.06%)	280 (8.71%)	1,238 (10.30%)	1,174 (10.57%)	3,950 (10.32%)
Declined to answer	51 (0.43%)	n/a	10 (0.31%)	48 (0.40%)	73 (0.66%)	183 (0.48%)
Unknown	596 (5.07%)	n/a	124 (3.86%)	598 (4.97%)	648 (5.84%)	1,979 (5.17%)
Ethnicity						
Hispanic or Latino	1,445 (12.28%)	20 (12.12%)	415 (12.90%)	1,764 (14.67%)	1,691 (15.23%)	5,335 (13.94%)
Not Hispanic or Latino	9,203 (78.23%)	132 (80.00%)	2,604 (80.97%)	9,543 (79.38%)	8,751 (78.81%)	30,233 (79.00%)
Declined to answer	59 (0.50%)	n/a	11 (0.34%)	55 (0.46%)	67 (0.60%)	193 (0.50%)
Unknown	1,057 (8.99%)	12 (7.27%)	186 (5.78%)	660 (5.49%)	595 (5.36%)	2,510 (6.56%)
Comorbidity						
Asthma	1,467 (12.47%)	16 (9.70%)	482 (14.99%)	1,756 (14.61%)	1,649 (14.85%)	5,370 (14.03%)
Chronic Lung Disease	845 (7.18%)	n/a	256 (7.96%)	985 (8.19%)	899 (8.10%)	2,993 (7.82%)
Chronic Obstructive Pulmonary Disease	2,010 (17.09%)	21 (12.73%)	625 (19.43%)	2,248 (18.70%)	1,990 (17.92%)	6,894 (18.01%)

The rate of influenza-associated hospitalization is shown in Figure 5. Figure 6 shows seasonal trends.

Figure 5: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019




Figure 6: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 9,642 hospitalizations of 8,142 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	2,041 (100.00%)	137 (100.00%)	1,717 (100.00%)	3,537 (100.00%)	710 (100.00%)	8,142 (100.00%)
Age Group						
< 6 months	50 (2.45%)	11 (8.03%)	54 (3.15%)	164 (4.64%)	30 (4.23%)	309 (3.80%)
6 - <12 months	70 (3.43%)	n/a	90 (5.24%)	118 (3.34%)	29 (4.08%)	312 (3.83%)
1 - <2 years	71 (3.48%)	21 (15.33%)	134 (7.80%)	170 (4.81%)	34 (4.79%)	430 (5.28%)
2 - 4 years	83 (4.07%)	22 (16.06%)	216 (12.58%)	280 (7.92%)	46 (6.48%)	647 (7.95%)
5 - 17 years	57 (2.79%)	n/a	104 (6.06%)	185 (5.23%)	39 (5.49%)	394 (4.84%)
18 - 49 years	227 (11.12%)	16 (11.68%)	194 (11.30%)	341 (9.64%)	92 (12.96%)	870 (10.69%)
50 - 64 years	391 (19.16%)	17 (12.41%)	258 (15.03%)	545 (15.41%)	127 (17.89%)	1,338 (16.43%)
65 - 74 years	396 (19.40%)	16 (11.68%)	256 (14.91%)	642 (18.15%)	116 (16.34%)	1,426 (17.51%)
75 - 84 years	415 (20.33%)	13 (9.49%)	250 (14.56%)	659 (18.63%)	97 (13.66%)	1,434 (17.61%)
85+ years	281 (13.77%)	n/a	161 (9.38%)	433 (12.24%)	100 (14.08%)	982 (12.06%)
Sex						
Female	1,178 (57.72%)	67 (48.91%)	1,004 (58.47%)	2,041 (57.70%)	435 (61.27%)	4,725 (58.03%)
Male	858 (42.04%)	70 (51.09%)	710 (41.35%)	1,491 (42.15%)	274 (38.59%)	3,403 (41.80%)
Unknown	n/a	n/a	n/a	n/a	n/a	14 (0.17%)
Race						
White	1,448 (70.95%)	60 (43.80%)	1,109 (64.59%)	2,282 (64.52%)	407 (57.32%)	5,306 (65.17%)
Black or African American	204 (10.00%)	19 (13.87%)	179 (10.43%)	358 (10.12%)	94 (13.24%)	854 (10.49%)
Asian	65 (3.18%)	n/a	74 (4.31%)	165 (4.66%)	32 (4.51%)	341 (4.19%)

Native Hawaiian or Other Pacific Islander	11 (0.54%)	n/a	14 (0.82%)	10 (0.28%)	n/a	37 (0.45%)		
American Indian or Alaska Native	13 (0.64%)	n/a	n/a	24 (0.68%)	n/a	48 (0.59%)		
Other Race	209 (10.24%)	47 (34.31%)	244 (14.21%)	465 (13.15%)	122 (17.18%)	1,087 (13.35%)		
Declined to answer	n/a	n/a	12 (0.70%)	22 (0.62%)	n/a	48 (0.59%)		
Unknown	85 (4.16%)	n/a	72 (4.19%)	211 (5.97%)	38 (5.35%)	421 (5.17%)		
Ethnicity								
Hispanic or Latino	243 (11.91%)	42 (30.66%)	293 (17.06%)	606 (17.13%)	140 (19.72%)	1,324 (16.26%)		
Not Hispanic or Latino	1,642 (80.45%)	86 (62.77%)	1,322 (76.99%)	2,716 (76.79%)	530 (74.65%)	6,296 (77.33%)		
Declined to answer	11 (0.54%)	n/a	n/a	19 (0.54%)	n/a	39 (0.48%)		
Unknown	145 (7.10%)	n/a	98 (5.71%)	196 (5.54%)	36 (5.07%)	483 (5.93%)		
Comorbidity								
Asthma	287 (14.06%)	17 (12.41%)	258 (15.03%)	504 (14.25%)	133 (18.73%)	1,199 (14.73%)		
Chronic Lung Disease	224 (10.98%)	n/a	152 (8.85%)	284 (8.03%)	55 (7.75%)	722 (8.87%)		
Chronic Obstructive Pulmonary Disease	409 (20.04%)	n/a	275 (16.02%)	571 (16.14%)	114 (16.06%)	1,378 (16.92%)		

The rate of HMPV-associated hospitalization is shown in Figure 7. Figure 8 shows seasonal trends.

Figure 7: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 8: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Parainfluenza virus

Our parainfluenza virus study population consists of 9,286 hospitalizations of 7,595 unique patients (Table 5).

Table 5: Parainfluenza virus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	1,005 (100.00%)	929 (100.00%)	1,616 (100.00%)	3,208 (100.00%)	837 (100.00%)	7,595 (100.00%)
Age Group						
< 6 months	56 (5.57%)	58 (6.24%)	103 (6.37%)	178 (5.55%)	53 (6.33%)	448 (5.90%)
6 - <12 months	30 (2.99%)	46 (4.95%)	69 (4.27%)	132 (4.11%)	21 (2.51%)	298 (3.92%)
1 - <2 years	47 (4.68%)	76 (8.18%)	102 (6.31%)	157 (4.89%)	58 (6.93%)	440 (5.79%)
2 - 4 years	61 (6.07%)	89 (9.58%)	158 (9.78%)	240 (7.48%)	62 (7.41%)	610 (8.03%)
5 - 17 years	49 (4.88%)	75 (8.07%)	114 (7.05%)	193 (6.02%)	59 (7.05%)	490 (6.45%)
18 - 49 years	102 (10.15%)	132 (14.21%)	195 (12.07%)	368 (11.47%)	115 (13.74%)	912 (12.01%)
50 - 64 years	184 (18.31%)	149 (16.04%)	249 (15.41%)	506 (15.77%)	118 (14.10%)	1,206 (15.88%)
65 - 74 years	171 (17.01%)	128 (13.78%)	258 (15.97%)	503 (15.68%)	131 (15.65%)	1,191 (15.68%)
75 - 84 years	176 (17.51%)	107 (11.52%)	213 (13.18%)	561 (17.49%)	135 (16.13%)	1,192 (15.69%)
85+ years	129 (12.84%)	69 (7.43%)	155 (9.59%)	370 (11.53%)	85 (10.16%)	808 (10.64%)
Sex						
Female	540 (53.73%)	475 (51.13%)	876 (54.21%)	1,704 (53.12%)	459 (54.84%)	4,054 (53.38%)
Male	461 (45.87%)	450 (48.44%)	735 (45.48%)	1,496 (46.63%)	376 (44.92%)	3,518 (46.32%)
Unknown	n/a	n/a	n/a	n/a	n/a	22 (0.29%)
Race				'		
White	665 (66.17%)	549 (59.10%)	978 (60.52%)	1,990 (62.03%)	477 (56.99%)	4,659 (61.34%)
Black or African American	116 (11.54%)	142 (15.29%)	191 (11.82%)	376 (11.72%)	119 (14.22%)	944 (12.43%)
Asian	57 (5.67%)	40 (4.31%)	95 (5.88%)	176 (5.49%)	36 (4.30%)	404 (5.32%)
Native Hawaiian or Other Pacific Islander	12 (1.19%)	n/a	n/a	15 (0.47%)	n/a	45 (0.59%)
American Indian or Alaska Native	n/a	n/a	14 (0.87%)	25 (0.78%)	n/a	56 (0.74%)
Other Race	99 (9.85%)	140 (15.07%)	228 (14.11%)	438 (13.65%)	130 (15.53%)	1,035 (13.63%)
Declined to answer	n/a	n/a	10 (0.62%)	20 (0.62%)	n/a	44 (0.58%)
Unknown	42 (4.18%)	43 (4.63%)	87 (5.38%)	162 (5.05%)	47 (5.62%)	408 (5.37%)
Ethnicity						
Hispanic or Latino	94 (9.35%)	149 (16.04%)	259 (16.03%)	530 (16.52%)	161 (19.24%)	1,193 (15.71%)
Not Hispanic or Latino	803 (79.90%)	695 (74.81%)	1,248 (77.23%)	2,472 (77.06%)	628 (75.03%)	5,846 (76.97%)
Declined to answer	n/a	n/a	10 (0.62%)	18 (0.56%)	n/a	37 (0.49%)
Unknown	104 (10.35%)	83 (8.93%)	99 (6.13%)	188 (5.86%)	45 (5.38%)	519 (6.83%)

Comorbidity						
Asthma	151 (15.02%)	115 (12.38%)	233 (14.42%)	462 (14.40%)	117 (13.98%)	1,078 (14.19%)
Chronic Lung Disease	113 (11.24%)	62 (6.67%)	154 (9.53%)	273 (8.51%)	60 (7.17%)	662 (8.72%)
Chronic Obstructive Pulmonary Disease	208 (20.70%)	144 (15.50%)	280 (17.33%)	569 (17.74%)	151 (18.04%)	1,352 (17.80%)

The rate of parainfluenza virus-associated hospitalization is shown in Figure 9. Figure 10 shows seasonal trends.

Figure 9: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 201



Figure 10: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 27,462 hospitalizations of 21,770 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
NI	4,266	1,583	3,409	6,238	6,274	21,770
N	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)
Age Group						
< 6 months	850 (19.92%)	474 (29.94%)	723 (21.21%)	1,268 (20.33%)	862 (13.74%)	4,177 (19.19%)
6 - <12 months	314 (7.36%)	132 (8.34%)	264 (7.74%)	450 (7.21%)	338 (5.39%)	1,498 (6.88%)
1 - <2 years	317 (7.43%)	180 (11.37%)	328 (9.62%)	582 (9.33%)	395 (6.30%)	1,802 (8.28%)
2 - 4 years	311 (7.29%)	140 (8.84%)	340 (9.97%)	671 (10.76%)	366 (5.83%)	1,828 (8.40%)
5 - 17 years	74 (1.73%)	40 (2.53%)	119 (3.49%)	221 (3.54%)	175 (2.79%)	629 (2.89%)
18 - 49 years	229 (5.37%)	126 (7.96%)	292 (8.57%)	454 (7.28%)	517 (8.24%)	1,618 (7.43%)
50 - 64 years	484 (11.35%)	161 (10.17%)	363 (10.65%)	600 (9.62%)	848 (13.52%)	2,456 (11.28%)
65 - 74 years	588 (13.78%)	140 (8.84%)	374 (10.97%)	743 (11.91%)	970 (15.46%)	2,815 (12.93%)
75 - 84 years	645 (15.12%)	122 (7.71%)	375 (11.00%)	765 (12.26%)	1,011 (16.11%)	2,918 (13.40%)
85+ years	454 (10.64%)	68 (4.30%)	231 (6.78%)	484 (7.76%)	792 (12.62%)	2,029 (9.32%)
Sex						
Female	2,304 (54.01%)	851 (53.76%)	1,755 (51.48%)	3,270 (52.42%)	3,472 (55.34%)	11,652 (53.52%)
Male	1,949 (45.69%)	727 (45.93%)	1,650 (48.40%)	2,947 (47.24%)	2,787 (44.42%)	10,060 (46.21%)
Unknown	13 (0.30%)	n/a	n/a	21 (0.34%)	15 (0.24%)	58 (0.27%)
Race						
White	2,646 (62.03%)	831 (52.50%)	2,067 (60.63%)	3,751 (60.13%)	4,031 (64.25%)	13,326 (61.21%)
Black or African American	530 (12.42%)	347 (21.92%)	451 (13.23%)	784 (12.57%)	773 (12.32%)	2,885 (13.25%)
Asian	165 (3.87%)	51 (3.22%)	183 (5.37%)	408 (6.54%)	289 (4.61%)	1,096 (5.03%)
Native Hawaiian or Other Pacific Islander	35 (0.82%)	12 (0.76%)	66 (1.94%)	126 (2.02%)	84 (1.34%)	323 (1.48%)
American Indian or Alaska Native	21 (0.49%)	n/a	42 (1.23%)	48 (0.77%)	44 (0.70%)	163 (0.75%)
Other Race	618 (14.49%)	260 (16.42%)	417 (12.23%)	727 (11.65%)	616 (9.82%)	2,638 (12.12%)
Declined to answer	11 (0.26%)	n/a	15 (0.44%)	39 (0.63%)	48 (0.77%)	119 (0.55%)
Unknown	240 (5.63%)	64 (4.04%)	161 (4.72%)	355 (5.69%)	389 (6.20%)	1,220 (5.60%)
Ethnicity						
Hispanic or Latino	716 (16.78%)	326 (20.59%)	603 (17.69%)	1,118 (17.92%)	993 (15.83%)	3,756 (17.25%)
Not Hispanic or Latino	3,138 (73.56%)	1,148 (72.52%)	2,615 (76.71%)	4,694 (75.25%)	4,872 (77.65%)	16,467 (75.64%)
Declined to answer	12 (0.28%)	n/a	17 (0.50%)	51 (0.82%)	48 (0.77%)	135 (0.62%)
Unknown	400 (9.38%)	102 (6.44%)	174 (5.10%)	375 (6.01%)	361 (5.75%)	1,412 (6.49%)
Comorbidity						
Asthma	495 (11.60%)	131 (8.28%)	366 (10.74%)	746 (11.96%)	854 (13.61%)	2,592 (11.91%)
Chronic Lung Disease	284 (6.66%)	65 (4.11%)	177 (5.19%)	356 (5.71%)	454 (7.24%)	1,336 (6.14%)
Chronic Obstructive Pulmonary Disease	729 (17.09%)	144 (9.10%)	447 (13.11%)	876 (14.04%)	1,077 (17.17%)	3,273 (15.03%)

The rate of RSV-associated hospitalization is shown in Figure 11. Figure 12 shows seasonal trends.

Figure 11: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 12: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Rhinovirus

Our rhinovirus study population consists of 42,607 hospitalizations of 34,700 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	6,168 (100.00%)	4,784 (100.00%)	6,649 (100.00%)	11,842 (100.00%)	5,257 (100.00%)	34,700 (100.00%)
Age Group						
< 6 months	399 (6.47%)	309 (6.46%)	553 (8.32%)	745 (6.29%)	303 (5.76%)	2,309 (6.65%)
6 - <12 months	205 (3.32%)	222 (4.64%)	333 (5.01%)	387 (3.27%)	198 (3.77%)	1,345 (3.88%)
1 - <2 years	313 (5.07%)	395 (8.26%)	640 (9.63%)	750 (6.33%)	294 (5.59%)	2,392 (6.89%)
2 - 4 years	431 (6.99%)	496 (10.37%)	1,013 (15.24%)	1,221 (10.31%)	429 (8.16%)	3,590 (10.35%)
5 - 17 years	435 (7.05%)	622 (13.00%)	984 (14.80%)	1,580 (13.34%)	598 (11.38%)	4,219 (12.16%)
18 - 49 years	981 (15.90%)	959 (20.05%)	871 (13.10%)	1,825 (15.41%)	913 (17.37%)	5,549 (15.99%)
50 - 64 years	1,089 (17.66%)	642 (13.42%)	714 (10.74%)	1,561 (13.18%)	755 (14.36%)	4,761 (13.72%)

65 - 74 years	918 (14.88%)	498 (10.41%)	671 (10.09%)	1,535 (12.96%)	729 (13.87%)	4,351 (12.54%)
75 - 84 years	816 (13.23%)	396 (8.28%)	529 (7.96%)	1,337 (11.29%)	628 (11.95%)	3,706 (10.68%)
85+ years	581 (9.42%)	245 (5.12%)	341 (5.13%)	901 (7.61%)	410 (7.80%)	2,478 (7.14%)
Sex						
Female	3,042 (49.32%)	2,362 (49.37%)	3,137 (47.18%)	5,888 (49.72%)	2,661 (50.62%)	17,090 (49.25%)
Male	3,107 (50.37%)	2,406 (50.29%)	3,498 (52.61%)	5,927 (50.05%)	2,581 (49.10%)	17,519 (50.49%)
Unknown	19 (0.31%)	16 (0.33%)	14 (0.21%)	27 (0.23%)	15 (0.29%)	91 (0.26%)
Race						
White	3,872 (62.78%)	2,680 (56.02%)	3,621 (54.46%)	6,700 (56.58%)	2,971 (56.52%)	19,844 (57.19%)
Black or African American	862 (13.98%)	793 (16.58%)	1,038 (15.61%)	1,805 (15.24%)	819 (15.58%)	5,317 (15.32%)
Asian	264 (4.28%)	220 (4.60%)	371 (5.58%)	605 (5.11%)	215 (4.09%)	1,675 (4.83%)
Native Hawaiian or Other Pacific Islander	43 (0.70%)	42 (0.88%)	50 (0.75%)	43 (0.36%)	21 (0.40%)	199 (0.57%)
American Indian or Alaska Native	44 (0.71%)	34 (0.71%)	51 (0.77%)	106 (0.90%)	32 (0.61%)	267 (0.77%)
Other Race	733 (11.88%)	798 (16.68%)	1,107 (16.65%)	1,750 (14.78%)	807 (15.35%)	5,195 (14.97%)
Declined to answer	29 (0.47%)	20 (0.42%)	40 (0.60%)	85 (0.72%)	58 (1.10%)	232 (0.67%)
Unknown	321 (5.20%)	191 (3.99%)	371 (5.58%)	748 (6.32%)	334 (6.35%)	1,971 (5.68%)
Ethnicity						
Hispanic or Latino	775 (12.56%)	766 (16.01%)	1,195 (17.97%)	2,178 (18.39%)	953 (18.13%)	5,867 (16.91%)
Not Hispanic or Latino	4,834 (78.37%)	3,666 (76.63%)	5,005 (75.27%)	8,856 (74.78%)	3,952 (75.18%)	26,313 (75.83%)
Declined to answer	27 (0.44%)	23 (0.48%)	35 (0.53%)	72 (0.61%)	46 (0.88%)	203 (0.59%)
Unknown	532 (8.63%)	329 (6.88%)	414 (6.23%)	736 (6.22%)	306 (5.82%)	2,317 (6.68%)
Comorbidity						
Asthma	1,037 (16.81%)	780 (16.30%)	1,043 (15.69%)	1,966 (16.60%)	859 (16.34%)	5,685 (16.38%)
Chronic Lung Disease	639 (10.36%)	332 (6.94%)	388 (5.84%)	783 (6.61%)	368 (7.00%)	2,510 (7.23%)
Chronic Obstructive Pulmonary Disease	1,195 (19.37%)	614 (12.83%)	691 (10.39%)	1,538 (12.99%)	704 (13.39%)	4,742 (13.67%)

The rate of rhinovirus-associated hospitalization is shown in Figure 13. Figure 14 shows seasonal trends.

Figure 13: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 14: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Infants and children (age 0-4)

Our infants and children study population consists of 35,268 hospitalizations of 28,276 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	4,362	3,630	7,198	8,876	4,210	28,276
	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)
Age Group						
< 6 months	1,595 (36.57%)	1,423 (39.20%)	2,474 (34.37%)	2,811 (31.67%)	1,481 (35.18%)	9,784 (34.60%)
6 - <12 months	724 (16.60%)	486 (13.39%)	1,012 (14.06%)	1,323 (14.91%)	695 (16.51%)	4,240 (15.00%)
1 - <2 years	911 (20.88%)	808 (22.26%)	1,525 (21.19%)	1,900 (21.41%)	920 (21.85%)	6,064 (21.45%)
2 - 4 years	1,132 (25.95%)	913 (25.15%)	2,187 (30.38%)	2,842 (32.02%)	1,114 (26.46%)	8,188 (28.96%)
Sex						
Female	1,910 (43.79%)	1,556 (42.87%)	3,048 (42.35%)	3,816 (42.99%)	1,844 (43.80%)	12,174
						(43.05%)
Male	2,432 (55.75%)	2,062 (56.80%)	4,140 (57.52%)	5,037 (56.75%)	2,360 (56.06%)	16,031
						(56.69%)
Unknown	20 (0.46%)	12 (0.33%)	10 (0.14%)	23 (0.26%)	n/a	71 (0.25%)

Race						
White	1,930 (44.25%)	1,617 (44.55%)	3,360 (46.68%)	4,046 (45.58%)	1,959 (46.53%)	12,912 (45.66%)
Black or African American	701 (16.07%)	713 (19.64%)	1,153 (16.02%)	1,353 (15.24%)	634 (15.06%)	4,554 (16.11%)
Asian	268 (6.14%)	177 (4.88%)	492 (6.84%)	723 (8.15%)	291 (6.91%)	1,951 (6.90%)
Native Hawaiian or Other Pacific Islander	89 (2.04%)	65 (1.79%)	162 (2.25%)	194 (2.19%)	130 (3.09%)	640 (2.26%)
American Indian or Alaska Native	32 (0.73%)	22 (0.61%)	79 (1.10%)	105 (1.18%)	41 (0.97%)	279 (0.99%)
Other Race	1,044 (23.93%)	855 (23.55%)	1,414 (19.64%)	1,645 (18.53%)	737 (17.51%)	5,695 (20.14%)
Declined to answer	16 (0.37%)	18 (0.50%)	39 (0.54%)	66 (0.74%)	61 (1.45%)	200 (0.71%)
Unknown	282 (6.46%)	163 (4.49%)	499 (6.93%)	744 (8.38%)	357 (8.48%)	2,045 (7.23%)
Ethnicity						
Hispanic or Latino	1,213 (27.81%)	902 (24.85%)	1,722 (23.92%)	2,351 (26.49%)	1,088 (25.84%)	7,276 (25.73%)
Not Hispanic or Latino	2,710 (62.13%)	2,441 (67.25%)	4,935 (68.56%)	5,836 (65.75%)	2,803 (66.58%)	18,725 (66.22%)
Declined to answer	19 (0.44%)	19 (0.52%)	38 (0.53%)	59 (0.66%)	41 (0.97%)	176 (0.62%)
Unknown	420 (9.63%)	268 (7.38%)	503 (6.99%)	630 (7.10%)	278 (6.60%)	2,099 (7.42%)
Virus						
COVID	134 (3.07%)	950 (26.17%)	1,960 (27.23%)	851 (9.59%)	373 (8.86%)	4,268 (15.09%)
HMPV	274 (6.28%)	59 (1.63%)	494 (6.86%)	732 (8.25%)	139 (3.30%)	1,698 (6.01%)
RSV	1,792 (41.08%)	926 (25.51%)	1,655 (22.99%)	2,971 (33.47%)	1,961 (46.58%)	9,305 (32.91%)
influenza	620 (14.21%)	n/a	118 (1.64%)	512 (5.77%)	319 (7.58%)	1,573 (5.56%)
parainfluenza virus	194 (4.45%)	269 (7.41%)	432 (6.00%)	707 (7.97%)	194 (4.61%)	1,796 (6.35%)
rhinovirus	1,348 (30.90%)	1,422 (39.17%)	2,539 (35.27%)	3,103 (34.96%)	1,224 (29.07%)	9,636 (34.08%)
Comorbidity						
Asthma	256 (5.87%)	196 (5.40%)	382 (5.31%)	531 (5.98%)	265 (6.29%)	1,630 (5.76%)
Chronic Lung Disease	33 (0.76%)	15 (0.41%)	29 (0.40%)	49 (0.55%)	20 (0.48%)	146 (0.52%)
Chronic Obstructive Pulmonary Disease	n/a	n/a	n/a	12 (0.14%)	n/a	28 (0.10%)

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 15. Figure 16 shows the same data stacked to represent the combined impact of the viruses.

Figure 15: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five




Figure 16: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 242,265 hospitalizations of 225,996 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	30,325	59,420	61,651	48,883	25,717	225,996
	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)	(100.00%)
Age Group						
65 - 74 years	12,775	25,625	23,795	16,506	8,675 (33.73%)	87,376
	(42.13%)	(43.13%)	(38.60%)	(33.77%)		(38.66%)
75 - 84 years	10,981	21,793	23,323	19,064	10,049	85,210
	(36.21%)	(36.68%)	(37.83%)	(39.00%)	(39.08%)	(37.70%)
85+ years	6,569 (21.66%)	12,002	14,533	13,313	6,993 (27.19%)	53,410
		(20.20%)	(23.57%)	(27.23%)		(23.63%)
Sex						
Female	15,688	29,846	31,617	26,056	13,847	117,054
	(51.73%)	(50.23%)	(51.28%)	(53.30%)	(53.84%)	(51.79%)
Male	14,562	29,341	29,785	22,697	11,817	108,202
	(48.02%)	(49.38%)	(48.31%)	(46.43%)	(45.95%)	(47.88%)

Unknown	75 (0.25%)	233 (0.39%)	247 (0.40%)	130 (0.27%)	53 (0.21%)	738 (0.33%)
Race						
White	19,911 (65.66%)	46,274 (77.88%)	48,775 (79.11%)	37,454 (76.62%)	19,310 (75.09%)	171,724 (75.99%)
Black or African American	4,688 (15.46%)	5,261 (8.85%)	5,394 (8.75%)	4,100 (8.39%)	2,314 (9.00%)	21,757 (9.63%)
Asian	1,207 (3.98%)	1,556 (2.62%)	1,754 (2.85%)	1,882 (3.85%)	880 (3.42%)	7,279 (3.22%)
Native Hawaiian or Other Pacific Islander	39 (0.13%)	79 (0.13%)	117 (0.19%)	80 (0.16%)	37 (0.14%)	352 (0.16%)
American Indian or Alaska Native	68 (0.22%)	142 (0.24%)	190 (0.31%)	224 (0.46%)	86 (0.33%)	710 (0.31%)
Other Race	2,613 (8.62%)	3,821 (6.43%)	3,404 (5.52%)	3,081 (6.30%)	1,696 (6.59%)	14,615 (6.47%)
Declined to answer	114 (0.38%)	184 (0.31%)	206 (0.33%)	232 (0.47%)	130 (0.51%)	866 (0.38%)
Unknown	1,685 (5.56%)	2,103 (3.54%)	1,811 (2.94%)	1,830 (3.74%)	1,264 (4.92%)	8,693 (3.85%)
Ethnicity						
Hispanic or Latino	2,755 (9.08%)	4,822 (8.12%)	4,295 (6.97%)	3,755 (7.68%)	2,104 (8.18%)	17,731 (7.85%)
Not Hispanic or Latino	24,014 (79.19%)	49,142 (82.70%)	52,956 (85.90%)	41,998 (85.92%)	21,944 (85.33%)	190,054 (84.10%)
Declined to answer	138 (0.46%)	286 (0.48%)	284 (0.46%)	278 (0.57%)	155 (0.60%)	1,141 (0.50%)
Unknown	3,418 (11.27%)	5,170 (8.70%)	4,116 (6.68%)	2,852 (5.83%)	1,514 (5.89%)	17,070 (7.55%)
Virus						
COVID	19,384 (63.92%)	57,538 (96.83%)	56,253 (91.24%)	33,965 (69.48%)	15,120 (58.79%)	182,260 (80.65%)
HMPV	1,092 (3.60%)	36 (0.06%)	667 (1.08%)	1,734 (3.55%)	313 (1.22%)	3,842 (1.70%)
RSV	1,687 (5.56%)	330 (0.56%)	980 (1.59%)	1,992 (4.08%)	2,773 (10.78%)	7,762 (3.43%)
influenza	5,371 (17.71%)	73 (0.12%)	1,584 (2.57%)	5,985 (12.24%)	5,393 (20.97%)	18,406 (8.14%)
parainfluenza virus	476 (1.57%)	304 (0.51%)	626 (1.02%)	1,434 (2.93%)	351 (1.36%)	3,191 (1.41%)
rhinovirus	2,315 (7.63%)	1,139 (1.92%)	1,541 (2.50%)	3,773 (7.72%)	1,767 (6.87%)	10,535 (4.66%)
Comorbidity						
Asthma	2,568 (8.47%)	3,902 (6.57%)	4,940 (8.01%)	4,915 (10.05%)	2,879 (11.19%)	19,204 (8.50%)
Chronic Lung Disease	2,111 (6.96%)	3,431 (5.77%)	4,018 (6.52%)	3,926 (8.03%)	2,283 (8.88%)	15,769 (6.98%)
Chronic Obstructive Pulmonary Disease	5,490 (18.10%)	9,298 (15.65%)	11,698 (18.97%)	10,347 (21.17%)	5,960 (23.18%)	42,793 (18.94%)

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 17. Figure 18 shows the same data stacked to represent the combined impact of the viruses.

Figure 17: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older





Figure 18: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Discussion and Conclusion

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout February 2024 (20.0% decrease since end of January 2024). This is due the decrease in COVID- (-26.5%) and influenza-associated hospitalizations (-22.7%). Hospitalizations for all other monitored respiratory viruses increased, including those associated with HPMV, which more than doubled (+117.2%) throughout the month. COVID- and influenza-associated hospitalizations make up 2.3% and 1.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of February 2024, respiratory virus-associated hospitalizations accounted for 4.0% of all hospitalizations.

For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout February (-28.4%). For individual viruses, associated hospitalizations decreased when counts were above reporting thresholds. In the last week of February, 2.8% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.2%).

In the population over 65 years of age, there was a 19.9% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations all increased. HMPV-associated hospitalizations increased by 204.6% compared to the last week of January. In the last week of February, 5.2% of all hospitalizations in this age group were associated with a respiratory virus.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed March 14, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine.

2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518.

https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy